SCHEMBL4415075

SCHEMBL4415075

CC(=O)Nc1ccc(S(=O)(=O)N2CC3C(CNc4ccc(N5CCOCC5)c(F)c4)C3C2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.53
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 4/20 0.48
POLB P06746 4/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HPGD P15428 2/20 0.47
MEN1 O00255 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPK1 P28482 1/20 0.47
PKM P14618 3/20 0.45
LMNA P02545 3/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
MAOA P21397 1/20 0.44
PTGS1 P23219 1/20 0.44
MAOB P27338 1/20 0.44
CALML3 P27482 1/20 0.44
SDHA P31040 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417963 0.91 ALDH1A1 (0.48) KMT2AALDH1A1POLBNPSR1HPGD
SCHEMBL4417872 0.89 ALDH1A1 (0.45) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4419968 0.89 L3MBTL1 (0.46) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4415073 0.88 L3MBTL1 (0.50) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4423693 0.88 MAPK1 (0.44) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4414933 0.88 KMT2A (0.43) L3MBTL1KMT2AALDH1A1NPSR1HPGD
SCHEMBL4425190 0.88 MEN1 (0.46) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4417782 0.87 MAPT (0.45) L3MBTL1KMT2AALDH1A1POLBNPSR1
SCHEMBL4419259 0.87 MAOB (0.53) KMT2AALDH1A1NPSR1HPGDMEN1
SCHEMBL4413584 0.87 ALDH1A1 (0.48) KMT2AALDH1A1POLBSMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 L3MBTL1 1416/4885KMT2A 1892/4885ALDH1A1 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.